Are GLP-1 Weight Loss Drugs Cost-Effective? Systematic Review of Economic Evidence | Research

The takeaway

Systematic review of obesity drug economics finds GLP-1 agonists are cost-effective when long-term health benefits are considered, despite high upfront drug costs.

Cost-effective long-term
GLP-1 obesity drugs meet cost-effectiveness thresholds when prevented cardiovascular events, diabetes, and other complications are factored in

What the researchers found

GLP-1 obesity drugs generally meet cost-effectiveness thresholds when long-term complication prevention and quality of life improvements are factored into the analysis.

Why it matters

Insurance coverage and healthcare budgets depend on cost-effectiveness evidence. Demonstrating that GLP-1 drugs save money long-term through prevented complications supports broader coverage and access.

The numbers in context

Four databases were searched. PRISMA guidelines were followed. Specific cost-effectiveness ratios were analyzed across included studies.

How the study worked

Systematic review of published economic evaluations of obesity prevention and treatment medications, with focus on cost-effectiveness analysis methodology and outcomes.

Who was studied

Published economic evaluations of anti-obesity medications across healthcare systems

What this study cannot tell us

Economic models depend on assumptions about long-term outcomes, drug pricing, and complication rates. Different healthcare systems have different cost-effectiveness thresholds. Rapidly changing drug prices affect conclusions.

How to read the evidence

Strong evidence: systematic review of published economic evaluations with well-defined methodology assessment.

When this study was published

Published in 2025. Most comprehensive review of GLP-1 drug cost-effectiveness for obesity.

The bigger picture

The cost-effectiveness debate will determine who gets access to GLP-1 drugs. This review provides the evidence base for policymakers, insurers, and healthcare systems deciding whether to fund these expensive but effective medications.

Questions still open

At what drug price do GLP-1 obesity drugs become cost-effective for all obese patients?
Will biosimilar GLP-1 drugs dramatically improve cost-effectiveness?
Should cost-effectiveness models include productivity gains from weight loss?

Common questions

Are GLP-1 drugs worth the cost?

Economically, yes — when long-term benefits are considered. The ,000+/month drug cost is offset by preventing expensive complications: heart attacks, diabetes, kidney disease, joint replacements, and cancer. Cost-effectiveness improves in patients with more comorbidities.

Why won't my insurance cover GLP-1 drugs?

Many insurers focus on short-term drug costs rather than long-term savings. This review provides evidence that GLP-1 drugs are cost-effective long-term. Sharing this evidence with your insurer or appealing coverage decisions may help.

Read the original research

Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.

International journal of preventive medicine, 16, 56

View on PubMed ↗Publisher’s paper ↗

Citation

Afshari, Somaye; Khosravi, Majid; Zamandi, Mahmood; Rezapour, Aziz; Hadian, Marziye; Souresrafil, Aghdas; Mazaheri, Elaheh; Gallehzan, Nasrin Abolhasanbeigi. (2025). Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.. International journal of preventive medicine, 16, 56. https://doi.org/10.4103/ijpvm.ijpvm_368_24